Newly developed transarterial chemoembolization material: CDDP-lipiodol suspension

Cis-Diamminedichloroplatinum (CDDP)-lipiodol suspension (CLS) was developed as a transarterial chemoembolization (TACE) material. The CLS was injected into the proper hepatic artery or distal branches of patients with hepatocellular carcinoma. Strong anticancer effects were observed. Plasma concentr...

Full description

Saved in:
Bibliographic Details
Published inGastrointestinal radiology Vol. 14; no. 1; p. 46
Main Authors Araki, T, Hihara, T, Kachi, K, Matsusako, M, Ito, M, Kohno, K, Uchiyama, G
Format Journal Article
LanguageEnglish
Published United States 01.12.1989
Subjects
Carcinoma, Hepatocellular - therapy
Cisplatin - therapeutic use
Embolization, Therapeutic
Humans
Iodized Oil
Liver Neoplasms - therapy
Online AccessGet more information

Cover

More Information
Summary:Cis-Diamminedichloroplatinum (CDDP)-lipiodol suspension (CLS) was developed as a transarterial chemoembolization (TACE) material. The CLS was injected into the proper hepatic artery or distal branches of patients with hepatocellular carcinoma. Strong anticancer effects were observed. Plasma concentrations of total and filtrable CDDP following TACE were much lower than those following intravenous administration of CDDP solution. No major adverse complications were noted, presumably due to low CDDP concentrations in circulating plasma. The CLS appears to be an excellent TACE material.
ISSN:0364-2356
DOI:10.1007/BF01889153